nach oben

Erschienen in:

01.04.2013 | Original Article

Validation of the grip test and human activity profile for evaluation of physical performance during the intermediate phase after allogeneic hematopoietic stem cell transplantation

verfasst von: Maxi Kramer, Pia Heussner, Philipp Y. Herzberg, Holger Andree, Inken Hilgendorf, Malte Leithaeuser, Christian Junghanss, Mathias Freund, Daniel Wolff

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The aims of the presented study were to validate tools evaluating physical functioning (PF) after allogeneic hematopoietic stem cell transplantation (alloHSCT) and to analyze the impact of the clinical course on PF.

Methods

Forty patients undergoing alloHSCT were enrolled in a prospective trial which included evaluation of muscle strength (grip test, CITEC dynamometer), endurance (2-min walk test), anxiety and depression (Hospital Anxiety and Depression Scale), fatigue (Modified Fatigue Impact Scale and Brief Fatigue Inventory), and physical activity (Human Activity Profile—HAP) before (t1) and 1 (t2) and 3 (t3) months after alloHSCT.

Results

At t2, all patients showed a 6 % (p = 0.02) loss of muscle strength which was higher in patients with acute graft-versus-host disease (aGVHD) (12 %). While patients without aGVHD recovered at t3, the loss of muscle strength was progressive in patients with aGVHD. The grip test results correlated with the results of detailed measurement of muscle strength by CITEC dynamometer (r = 0.4–0.8, p = 0.05–0.001). Moreover, the HAP scores correlated with physical performance.

Conclusion

The results demonstrate that loss of PF occurs during the first month followed by a regain during the subsequent 2 months in the absence of aGVHD. The HAP and the grip test may serve as surrogate marker for the strength loss in the course of aGVHD.

Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354:1813–1826PubMedCrossRef

Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H, Gratwohl A et al (2006) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 37:439–449PubMedCrossRef

Pidala J, Anasetti C, Jim H (2009) Quality of life after allogeneic hematopoetic cell transplantation. Blood 114:7–19PubMedCrossRef

Wiskemann J, Huber G (2008) Physical exercise as adjuvant therapy for patients undergoing hematopoetic stem cell transplantation. Bone Marrow Transplant 41:321–329PubMedCrossRef

Wolff D, Herzberg PY, Heussner P, Mumm F, von Harsdorf S, Rieger K, Greinix H, Hahn J, Junghanss C, Holler E, Freund M (2007) Prospective evaluation of the NIH staging criteria in chronic GVHD and correlation to quality of life results of a German multicenter validation trial. Blood 110:(21a)

Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW et al (2006) Measuring therapeutic response in chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response criteria working group report. Blood Marrow Transplant 12:252–266CrossRef

Herzberg PY, Heussner P, Mumm F, Horak M, Hilgendorf I, von Harsdorf S, Hemmati P, Rieger K, Greinix H, Freund M, Holler E, Wolff D (2010) Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation. Blood Marrow Transplant 16:1707–1717CrossRef

Lee HJ, Oran B, Sabiba RM, Couriel DM, Shin K, Massey P, Neumann J, de Lima M, Champlin R, Giralt S (2006) Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy. Bone Marrow Transplant 38:299–303PubMedCrossRef

Lee SJ, Kim HT, Cutler C, Alyea EP, Soiffer RJ, Antin JH (2006) Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant 38:305–310PubMedCrossRef

10.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370PubMedCrossRef

11.

Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D (1999) Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 5:251–259PubMed

12.

Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK et al (1999) The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer 85:1186–1196PubMedCrossRef

13.

Daughton DM, Fix AJ, Kass I, Bell CW, Patil KD (1982) Maximum oxygen consumption and the ADAPT quality-of life scale. Arch Phys Med Rehabil 63:620–622PubMed

14.

Davidson M, Morton N (2007) A systematic review of the human activity profile. Clin Rehabil 21:151–162PubMedCrossRef

15.

Butland RJ, Pang J, Gross ER, Woodcoock AA, Geddes DM (1982) Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed) 284(6329):1607–1608CrossRef

16.

Solway S, Brooks D, Lacasse Y, Thomas S (2001) A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 119(1):256–270PubMedCrossRef

17.

Van der Ploeg RJ, Fidler V, Oosterhuis HJ (1991) Hand-held myometry: reference values. J Neurol Neurosurg Psychiatry 54:244–251PubMedCrossRef

18.

Van der Ploeg RJ, Oosterhuis HJ (1991) The “make/break test” as a diagnostic tool in functional weakness. J Neurol Neurosurg Psychiatry 54:248–251PubMedCrossRef

19.

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) Meeting report—consensus conference (1994 Houston, USA) on acute GVHD grading. Printed in. Bone Marrow Transplant 15(6):825–828PubMed

20.

Ashton LA, Myers S (2004) Serial grip strength testing—its role in assessment of wrist and hand disability. The Internet J Surg 5(2): 1528-1642

21.

Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Erlbaum, Hillsdale

22.

Kovalszki A, Schumaker GL, Klein A, Terrin N, White AC (2008) Reduced respiratory and skeletal muscle strength in survivors of sibling or unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant 41:965–969PubMedCrossRef

23.

White AC, Terrin N, Miller KB, Ryan HF (2005) Impaired respiratory and skeletal muscle strength in patients prior to hematopoietic stem-cell transplantation. Chest 128:145–152PubMedCrossRef

24.

Smith MA, Reid MB (2006) Redox modulation of contractile function in respiratory and limb skeletal muscle. Respir Physiol Neurobiol 151:229–241PubMedCrossRef

25.

Evens AM, Mehta J, Gordon LI (2004) Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplant 34:561–571PubMedCrossRef

26.

White AC, Sousa AM, Blumberg J, Ryan HF, Fanburg BL, Kayyali US (2006) Plasma anti-oxidants in subjects prior to hematopoietic stem cell transplantation. Bone Marrow Transplant 38:513–520PubMedCrossRef

27.

Li L, Chan L, Gerber LH (2009) Rehabilitation evaluation and treatment of patients with chronic graft versus host disease. In: Vogelsang GB, Pavletic SZ (eds) Chronic graft versus host disease: interdisciplinary management, vol 229. Cambridge University Press, Cambridge, pp 252–267CrossRef

28.

Hacker EH, Ferrans C, Verlen E, Ravandi F, van Besien K, Gelms J, Dieterle N (2006) Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant. Oncology Nursing Forum 33:614–624CrossRef

29.

Bevans MF, Mitchell S, Marden S (2008) The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT). Support Care Cancer 16:1243–1254PubMedCrossRef

30.

Wang XS, Shi Q, Williams LA, Cleeland CS, Mobley GM, Reuben JM, Lee BN, Giralt SA (2008) Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 113(8):2102–2109PubMedCrossRef

31.

Fife BL, Huster GA, Cornetta KG, Kennedy VN, Akard LP, Broun ER (2000) Longitudinal study of adaptation to the stress of bone marrow transplantation. J Clin Oncol 18(7):1539–1549PubMed

32.

Rantanen T, Harris T, Leveille SG, Visser M, Foley D, Masaki K et al (2000) Muscle strength and body mass index as long-term predictors of mortality in initially healthy men. J Gerontol 55:168–173CrossRef

33.

Lucia A, Earnest C, Perez M (2003) Cancer-related fatigue: can exercise physiology assist oncologists? Lancet Oncol 4:616–625PubMedCrossRef

34.

Willenbacher W, Mumm A, Rüther A, Weis J, Bartsch HH (1998) Somatic risk factors for intermediate and long-term sequelae after hematological stem cell therapy predictive for feasibility of a rehabilitation program. Oncology 21:217–223CrossRef

35.

Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM (1997) Steroid myopathy in cancer patients. Neurology 48:1234–1238PubMedCrossRef

36.

Wiskemann J, Dreger P, Schwerdtfeger R, Bondong A, Huber G, Kleindienst N, Ulrich CM, Bohus M (2011) Effects of a partly self-administered exercise program prior to, during and after allogeneic stem cell transplantation: a randomized controlled trial. Blood 117(9):2604–2613PubMedCrossRef

37.

Baumann FT, Zopf EM, Nykamp E, Kraut L, Schüle K, Elter T, Fauser AA, Bloch W (2011) Physical activity for patients undergoing an allogeneic hematopoietic stem cell transplantation: benefits of a moderate exercise intervention. Eur J Haematol 87(2):148–156PubMedCrossRef

Titel: Validation of the grip test and human activity profile for evaluation of physical performance during the intermediate phase after allogeneic hematopoietic stem cell transplantation
verfasst von: Maxi Kramer
Pia Heussner
Philipp Y. Herzberg
Holger Andree
Inken Hilgendorf
Malte Leithaeuser
Christian Junghanss
Mathias Freund
Daniel Wolff
Publikationsdatum: 01.04.2013
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 4/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-012-1634-1

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Validation of the grip test and human activity profile for evaluation of physical performance during the intermediate phase after allogeneic hematopoietic stem cell transplantation